A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV

ACS Infectious Diseases

Volumn 1, Issue 1, 2015, Pages 4-41

  Bisacchi, Gregory S ^a   Manchester, John I ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

antibacterial; AZD5099; BL C43; BTA C223; clorobiocin; coumermycin; drug discovery; gyrase; GyrB; inhibitor; novobiocin; ParE; PK PD; RU79115; topoisomerase; VXc 486

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; COUMARIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; INDAZOLE DERIVATIVE; NOVOBIOCIN; PHENOL; PYRAZOLE; QUINAZOLINONE DERIVATIVE;

ACINETOBACTER BAUMANNII; BACTERIAL MEMBRANE; DRUG MECHANISM; DRUG PENETRATION; HISTORICAL PERIOD; INVESTIGATIVE PROCEDURES; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; X RAY CRYSTALLOGRAPHY;

EID: 84969286340     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/id500013t     Document Type: Review

References (234)

1. Fed. Regist. 2011, 76 (12), 3143.
2. Bryskier, A. In Antibiotics and Antibacterial Agents: Classifications and Structure-Activity Relationship; Bryskier, A., Ed.; Antimicrobial agents: antibacterials and antifungals; ASM Press: Washington, DC, 2005; pp 13-38.
3. Fernandes, P. (2006) Antibacterial discovery and development - the failure of success? Nat. Biotechnol. 24, 1497-1503 10.1038/nbt1206-1497
4. Gwynn, M. N., Portnoy, A., Rittenhouse, S. F., and Payne, D. J. (2010) Challenges of antibacterial discovery revisited Ann. N.Y. Acad. Sci. 1213, 5-19 10.1111/j.1749-6632.2010.05828.x
5. Infectious Diseases Society of America The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 2010, 50, 1081-1083. 10.1086/652237
6. Rogers, D. E. (1956) The current problem of staphylococcal infections Ann. Int. Med. 45, 748-781 10.7326/0003-4819-45-5-748
7. Colville, J. M., Gale, H. H., Cox, F., and Quinn, E. L. (1957) Clinical observations on the use of novobiocin in penicillin-resistant staphylococcal septicemia Antibiot. Annu. 5, 920-926
8. Welch, H. and Wright, W. W. (1955) The common identity of cathomycin and Streptonivicin Antibiot. Chemother. (Northfield Ill) 5, 670-673
9. Jones, W. F., Jr., Nichols, R. L., and Finland, M. (1956) Antibacterial activity of Streptonivicin and cathomycin, two new antibiotics J. Lab. Clin. Med. 47, 783-792
10. Rolland, G., Sensi, P., De Ferrari, G. A., Maffii, G., Timbal, M. T., and Silvestri, L. G. (1956) Novobiocin and several of its derivatives Farmaco Sci. 11, 549-561
11. Fairbrother, R. W. and Williams, B. L. (1956) Two new antibiotics: antibacterial activity of novobiocin and vancomycin Lancet 268, 1177-1179 10.1016/S0140-6736(56)90052-6
12. Finland, M. and Nichols, R. L. (1957) Current therapeutics. CXIV. Novobiocin Practitioner 179, 84-92
13. Kawaguchi, H., Tsukiura, H., Okanishi, M., Miyaki, T., Ohmori, T., Fujisawa, K., and Koshiyama, H. (1965) Studies on coumermycin, a new Antibiotic. I. Production, isolation and characterization of coumermycin A1 J. Antibiot. (Tokyo) 18, 1-10
14. Finland, M. and Nichols, R. L. (1957) Novobiocin Antibiot. Chemother. 4, 209-392
15. Morris, A. and Russell, A. D. (1968) Some aspects of novobiocin action on Escherichia coli and Staphylococcus aureus Experientia 24, 195-197 10.1007/BF02146985
16. Finland, M. (1959) Novobiocin Antibiot. Monogr. No. 12, 97-122
17. Finland, M., Foltz, E., Geraco, J. E., Kirby, W. M., Quinn, E. L., Romansky, M. J., and Yow, E. M. (1959) The current status of erythromycin, kanamycin, novobiocin, oleandomycin, ristocetin, and vancomycin, with particular reference to their use in staphylococcal disease; panel discussion Antibiot Annu. 6, 1051-1072
18. David, N. A. and Burgner, P. R. (1956) Clinical effectiveness and safety of novobiocin Antibiotic Med. Clin. Ther. 2, 219-229
19. Berger, J. and Batcho, A. D. (1978) Coumarin-glycoside antibiotics J. Chromatogr. Libr. 15, 101-158
20. The panalba story. GP 1969, 40, 75-76.
21. Mintz, M. (1969) FDA and Panalba: a conflict of commercial, therapeutic goals? Science 165, 875-881 10.1126/science.165.3896.875
22. Wright, W. W., Putman, L. E., and Welch, H. (1956) Novobiocin; serum concentrations and urinary excretion following oral administration in man Antibiotic Med. Clin. Ther. 2, 311-316
23. Garry, M. W. (1958) A clinical evaluation of the parenteral use of novobiocin Am. J. Med. Sci. 236, 330-335 10.1097/00000441-195809000-00007
24. Kirby, W. M., Hudson, D. G., and Noyes, W. D. (1956) Clinical and laboratory studies of novobiocin, a new antibiotic AMA Arch. Int. Med. 98, 1-7 10.1001/archinte.1956.00250250007001
25. Simon, H. J. and Rogers, D. E. (1957) Agranulocytosis associated with novobiocin administration: report of a case Ann. Int. Med. 46, 778-783 10.7326/0003-4819-46-4-778
26. Conrad, M. E., Jr., Knochel, J. P., and Crosby, W. H. (1960) Novobiocin jaundice: demonstration of a hemolytic state Antibiotic Med. Clin. Ther. 7, 382-385
27. Walsh, T. J., Standiford, H. C., Reboli, A. C., John, J. F., Mulligan, M. E., Ribner, B. S., Montgomerie, J. Z., Goetz, M. B., Mayhall, C. G., and Rimland, D. (1993) Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome Antimicrob. Agents Chemother. 37, 1334-1342 10.1128/AAC.37.6.1334
28. Hahm, H. A., Armstrong, D. K., Chen, T. L., Grochow, L., Passos-Coelho, J., Goodman, S. N., Davidson, N. E., and Kennedy, M. J. (2000) Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study Biol. Blood Marrow Transplant. 6, 335-343 10.1016/S1083-8791(00)70059-0
29. Murren, J. R., DiStasio, S. A., Lorico, A., McKeon, A., Zuhowski, E. G., Egorin, M. J., Sartorelli, A. C., and Rappa, G. (2000) Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies Cancer J. 6, 256-265
30. Clin-Alert: October 4, 1969. Clin-Alert 1969, 7, 74-77. 10.1177/006947706900700119
31. Welch, H. and Marti-Ibanez, F. In The Antibiotic Saga; The Medical Encyclopedia, Inc.: New York, 1960; pp 85.
32. Woodruff, H. B. and McDaniel, L. E. (1958) Antibiotic approach Strategy of Chemotherapy: 8th Symposium. Society for General Microbiology 29
33. Berger, J., Schocher, A. J., Batcho, A. D., Pecherer, B., Keller, O., Maricq, J., Karr, A. E., Vaterlaus, B. P., Furlenmeier, A., and Spiegelberg, H. (1965) Production, isolation, and synthesis of the coumermycins (sugordomycins), a new streptomycete antibiotic complex Antimicrob. Agents Chemother. (Bethesda) 5, 778-785
34. Godfrey, J. C. and Price, K. E. (1972) Structure-activity relationships in coumermycins Adv. Appl. Microbiol. 15, 231-296
35. Grunberg, E. and Bennett, M. (1965) Chemotherapeutic properties of coumermycin A1 Antimicrob. Agents Chemother. (Bethesda) 5, 786-788
36. Michaeli, D., Meyers, B. R., and Weinstein, L. (1969) Microbiological and pharmacological study of a new antibiotics, coumermycin A1 Antimicrob. Agents Chemother. (Bethesda) 9, 463-467
37. Kaplan, S. A. (1970) Pharmacokinetic profile of coumermycin A1 J. Pharm. Sci. 59, 309-313 10.1002/jps.2600590306
38. Newmark, H. L., Berger, J., and Thurø Carstensen, J. (1970) Coumermycin A1: biopharmaceutical studies II J. Pharm. Sci. 59, 1249-1251 10.1002/jps.2600590906
39. Cron, M. J., Godfrey, J. C., Hooper, I. R., Keil, J. G., Nettleton, D. E., Price, K. E., and Schmitz, H. In Progress in Antimicrobial and Anticancer Chemotherapy; Proceedings of the 6th Internation Congress of Chemotherapy; University Park Press: Baltimore, MD, and Manchester, England, 1970; pp 1069.
40. Keil, J. G., Godfrey, J. C., Cron, M. J., Hooper, I. R., Nettleton, D. E., Price, K. E., and Schmitze, H. (1971) Structure-activity relationships in chemically modified coumermycin Pure Appl. Chem. 28, 571-602
41. Price, K. E., Chisholm, D. R., Leitner, F., and Misiek, M. (1969) Microbiological and pharmacological evaluation of BL-C 43, a new semisynthetic derivative of coumermycin A1 Antimicrob. Agents Chemother. (Bethesda) 9, 209-218
42. Mancy, D., Ninet, L., and Preud'Homme, J. DE1907556 A, 1969.
43. Ueda, Y., Chuang, J. M., Crast, L. B., and Partyka, R. A. (1988) A selective cleavage of the oxazole moiety in noviosylcoumarin antibiotics. A new process to key intermediates for coumermycin analog synthesis J. Org. Chem. 53, 5107-5113 10.1021/jo00256a037
44. Ueda, Y., Chuang, J. M., Crast, L. B., Jr., and Partyka, R. A. (1989) Synthesis and in vitro activity of new semi-synthetic coumermycin analogs: chemical modification at the C-3 amide J. Antibiot. (Tokyo) 42, 1379-1392 10.7164/antibiotics.42.1379
45. Ueda, Y., Chuang, J. M., Fung-Tomc, J., and Partyka, R. A. (1994) Synthesis and in vitro antibacterial activity of new semi-synthetic noviosylcoumarin antibiotics: chemical modification at the C-3′ ester Bioorg. Med. Chem. Lett. 4, 1623-1628 10.1016/S0960-894X(01)80578-3
46. Walsh, T. J., Hansen, S. L., Tatem, B. A., Auger, F., and Standiford, H. C. (1985) Activity of novobiocin against methicillin-resistant Staphylococcus aureus J. Antimicrob. Chemother. 15, 435-440 10.1093/jac/15.4.435
47. Jones, R. N. (1989) Should novobiocin be clinically re-evaluated? Diagn. Microbiol. Infect. Dis. 12, 363-365 10.1016/0732-8893(89)90105-3
48. Standiford, H. C., Walsh, T. J., Drusano, G. L., Tatem, B. A., and Townsend, R. J. (1993) Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination Diagn. Microbiol. Infect. Dis. 17, 135-142 10.1016/0732-8893(93)90024-2
49. Goetschi, E. Personal communication.
50. Arisawa, M., Goetschi, E., Kamiyama, T., Masciadri, R., Shimada, H., Watanabe, J., Hebeisen, P., and Link, H. EP92/00809, 1992.
51. Goetschi, E., Angehrn, P., Gmuender, H., Hebeisen, P., Link, H., Masciadri, R., and Nielsen, J. (1993) Cyclothialidine and its congeners: A new class of DNA gyrase inhibitors Pharmacol. Ther. 60, 367-380 10.1016/0163-7258(93)90017-8
52. Nakada, N., Shimada, H., Hirata, T., Aoki, Y., Kamiyama, T., Watanabe, J., and Arisawa, M. (1993) Biological characterization of cyclothialidine, a new DNA gyrase inhibitor Antimicrob. Agents Chemother. 37, 2656-2661 10.1128/AAC.37.12.2656
53. Goetschi, E., Angehrn, P., Gmuender, H., Hebeisen, P., Link, H., Masciadri, R., Nielsen, J., Reindl, P., and Ricklin, F. In The DNA Gyrase Inhibitor Cyclothialidine: Progenitor of a New Class of Antibacterial Agents; Medicinal Chemistry: Today and Tomorrow; Proceedings of the AFMC International Medicinal Chemistry Symposium, Sept 3-8 1995, Tokyo, 1997; pp 263-270.
54. Goetschi, E., Angehrn, P., Gmuender, H., Hebeisen, P., Kostrewa, D., Link, H., Luebbers, T., Masciadri, R., Reindl, P., Ricklin, F., and Theil, F. (2003) From the DNA gyrase inhibitor cyclothialidine to a new class of antibacterial agents Chimia 57, 184-186 10.2533/000942903777679505
55. Geiwiz, J., Goetschi, E., Hebeisen, P., Link, H., and Luebbers, T. EP675122 A2, 1995.
56. Rudolph, J., Theis, H., Hanke, R., Endermann, R., Johannsen, L., and Geschke, F. (2001) Seco-cyclothialidines: new concise synthesis, inhibitory activity toward bacterial and human DNA topoisomerases, and antibacterial properties J. Med. Chem. 44, 619-626 10.1021/jm0010623
57. Stieger, M., Angehrn, P., Wohlgensinger, B., and Gmuender, H. (1996) GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin Antimicrob. Agents Chemother. 40, 1060-1062
58. Oram, M., Dosanjh, B., Gormley, N. A., Smith, C. V., Fisher, L. M., Maxwell, A., and Duncan, K. (1996) Mode of action of GR122222X, a novel inhibitor of bacterial DNA gyrase Antimicrob. Agents Chemother. 40, 473-476
59. Lewis, R. J., Singh, O. M., Smith, C. V., Skarzynski, T., Maxwell, A., Wonacott, A. J., and Wigley, D. B. (1996) The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography EMBO J. 15, 1412-1420
60. Angehrn, P., Buchmann, S., Funk, C., Goetschi, E., Gmuender, H., Hebeisen, P., Kostrewa, D., Link, H., Luebbers, T., Masciadri, R., Nielsen, J., Reindl, P., Ricklin, F., Schmitt-Hoffmann, A., and Theil, F. P. (2004) New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine J. Med. Chem. 47, 1487-1513 10.1021/jm0310232
61. Angehrn, P., Goetschi, E., Gmuender, H., Hebeisen, P., Hennig, M., Kuhn, B., Luebbers, T., Reindl, P., Ricklin, F., and Schmitt-Hoffmann, A. (2011) A new DNA gyrase inhibitor subclass of the cyclothialidine familybased on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties J. Med. Chem. 54, 2207-2224 10.1021/jm1014023
62. Gellert, M., Mizuuchi, K., O'Dea, M. H., and Nash, H. A. (1976) DNA gyrase: an enzyme that introduces superhelical turns into DNA Proc. Natl. Acad. Sci. U.S.A. 73, 3872-3876 10.1073/pnas.73.11.3872
63. Gellert, M., O'Dea, M. H., Itoh, T., and Tomizawa, J. (1976) Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase Proc. Natl. Acad. Sci. U.S.A. 73, 4474-4478 10.1073/pnas.73.12.4474
64. Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T., and Tomizawa, J. (1977) Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity Proc. Natl. Acad. Sci. U.S.A. 74, 4772-4776 10.1073/pnas.74.11.4772
65. Kato, J., Nishimura, Y., Imamura, R., Niki, H., Hiraga, S., and Suzuki, H. (1990) New topoisomerase essential for chromosome segregation in E. coli Cell 63, 393-404 10.1016/0092-8674(90)90172-B
66. Kato, J., Suzuki, H., and Ikeda, H. (1992) Purification and characterization of DNA topoisomerase IV in Escherichia coli J. Biol. Chem. 267, 25676-25684
67. Takahata, M. and Nishino, T. (1988) DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity Antimicrob. Agents Chemother. 32, 1192-1195 10.1128/AAC.32.8.1192
68. Hopewell, R., Oram, M., Briesewitz, R., and Fisher, L. M. (1990) DNA cloning and organization of the Staphylococcus aureus gyrA and gyrB genes: close homology among gyrase proteins and implications for 4-quinolone action and resistance J. Bacteriol. 172, 3481-3484
69. Ferrero, L., Cameron, B., Manse, B., Lagneaux, D., Crouzet, J., Famechon, A., and Blanche, F. (1994) Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones Mol. Microbiol. 13, 641-653 10.1111/j.1365-2958.1994.tb00458.x
70. Pan, X. S. and Fisher, L. M. (1998) DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae Antimicrob. Agents Chemother. 42, 2810-2816
71. Pan, X. S. and Fisher, L. M. (1999) Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones Antimicrob. Agents Chemother. 43, 1129-1136
72. Sissi, C. and Palumbo, M. (2010) In front of and behind the replication fork: bacterial type IIA topoisomerases Cell. Mol. Life Sci. 67, 2001-2024 10.1007/s00018-010-0299-5
73. Laponogov, I., Sohi, M. K., Veselkov, D. A., Pan, X. S., Sawhney, R., Thompson, A. W., McAuley, K. E., Fisher, L. M., and Sanderson, M. R. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases Nat. Struct. Mol. Biol. 16, 667-669 10.1038/nsmb.1604
74. Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., Huang, J., Jones, E., Jones, J., Brown, K. K., Lewis, C. J., May, E. W., Saunders, M. R., Singh, O., Spitzfaden, C. E., Shen, C., Shillings, A., Theobald, A. J., Wohlkonig, A., Pearson, N. D., and Gwynn, M. N. (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 466, 935-940 10.1038/nature09197
75. Hooper, D. C. (2000) Mechanisms of action and resistance of older and newer fluoroquinolones Clin. Infect. Dis. 31, S24-8 10.1086/314056
76. Zhao, X., Xu, C., Domagala, J., and Drlica, K. (1997) DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance Proc. Natl. Acad. Sci. U.S.A. 94, 13991-13996 10.1073/pnas.94.25.13991
77. Hooper, D. C. In Mechanisms of Quinolone Resistance; Gram-Positive Pathog., 2 nd ed.; American Society for Microbiology: 2006; pp 821-833.
78. Grossman, T. H., Bartels, D. J., Mullin, S., Gross, C. H., Parsons, J. D., Liao, Y., Grillot, A. L., Stamos, D., Olson, E. R., Charifson, P. S., and Mani, N. (2007) Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds Antimicrob. Agents Chemother. 51, 657-666 10.1128/AAC.00596-06
79. Cambau, E., Matrat, S., Pan, X. S., Roth Dit Bettoni, R., Corbel, C., Aubry, A., Lascols, C., Driot, J. Y., and Fisher, L. M. (2009) Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli J. Antimicrob. Chemother. 63, 443-450 10.1093/jac/dkn528
80. Silver, L. L. Polypharmacology as an Emerging Trend in Antibacterial Discovery; Polypharmacology in Drug Discovery; John Wiley & Sons: 2012; pp 167-202.
81. Redgrave, L. S., Sutton, S. B., Webber, M. A., and Piddock, L. J. (2014) Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success Trends Microbiol. 22, 438-445 10.1016/j.tim.2014.04.007
82. Howard, B. M., Pinney, R. J., and Smith, J. T. (1993) Studies on mutational cross-resistance between ciprofloxacin, novobiocin and coumermycin in Escherichia coli and Staphylococcus warneri Microbios 75, 185-195
83. Hooper, D. C., Wolfson, J. S., McHugh, G. L., Winters, M. B., and Swartz, M. N. (1982) Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth Antimicrob. Agents Chemother. 22, 662-671 10.1128/AAC.22.4.662
84. Peng, H. and Marians, K. J. (1993) Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions J. Biol. Chem. 268, 24481-24490
85. Mani, N., Gross, C. H., Parsons, J. D., Hanzelka, B., Muh, U., Mullin, S., Liao, Y., Grillot, A. L., Stamos, D., Charifson, P. S., and Grossman, T. H. (2006) In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class Antimicrob. Agents Chemother. 50, 1228-1237 10.1128/AAC.50.4.1228-1237.2006
86. Heide, L. (2014) New aminocoumarin antibiotics as gyrase inhibitors Int. J. Med. Microbiol. 304, 31-36 10.1016/j.ijmm.2013.08.013
87. Vickers, A. A., O'Neill, A. J., and Chopra, I. (2007) Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies J. Antimicrob. Chemother. 60, 269-273 10.1093/jac/dkm191
88. Fujimoto-Nakamura, M., Ito, H., Oyamada, Y., Nishino, T., and Yamagishi, J. (2005) Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus Antimicrob. Agents Chemother. 49, 3810-3815 10.1128/AAC.49.9.3810-3815.2005
89. Phillips, J. W., Goetz, M. A., Smith, S. K., Zink, D. L., Polishook, J., Onishi, R., Salowe, S., Wiltsie, J., Allocco, J., Sigmund, J., Dorso, K., Lee, S., Skwish, S., de la Cruz, M., Martin, J., Vicente, F., Genilloud, O., Lu, J., Painter, R. E., Young, K., Overbye, K., Donald, R. G., and Singh, S. B. (2011) Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus Chem. Biol. 18, 955-965 10.1016/j.chembiol.2011.06.011
90. Drlica, K., Malik, M., Kerns, R. J., and Zhao, X. (2008) Quinolone-mediated bacterial death Antimicrob. Agents Chemother. 385-392 10.1128/AAC.01617-06
91. Stokes, N. R., Thomaides-Brears, H. B., Barker, S., Bennett, J. M., Berry, J., Collins, I., Czaplewski, L. G., Gamble, V., Lancett, P., Logan, A., Lunniss, C. J., Peasley, H., Pommier, S., Price, D., Smee, C., and Haydon, D. J. (2013) Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases Antimicrob. Agents Chemother. 57, 5977-5986 10.1128/AAC.00719-13
92. Nemeth, J., Oesch, G., and Kuster, S. P. (2014) Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis J. Antimicrob. Chemother. 10.1093/jac/dku379
93. Pankey, G. A. and Sabath, L. D. (2004) Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections Clin. Infect. Dis. 38, 864-870 10.1086/381972
94. Wigley, D. B., Davies, G. J., Dodson, E. J., Maxwell, A., and Dodson, G. (1991) Crystal structure of an N-terminal fragment of the DNA gyrase B protein Nature 351, 624-629 10.1038/351624a0
95. Tsai, F. T. F., Singh, O. M. P., Skarzynski, T., Wonacott, A. J., Weston, S., Tucker, A., Pauptit, R. A., Breeze, A. L., Poyser, J. P., O'Brien, R., Ladbury, J. E., and Wigley, D. B. (1997) The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin Proteins: Struct., Funct., Bioinf. 28, 41-52 10.1002/(SICI)1097-0134(199705)28:1<41::AID-PROT4>3.3.CO;2-B
96. Wei, H., Ruthenburg, A. J., Bechis, S. K., and Verdine, G. L. (2005) Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase J. Biol. Chem. 280, 37041-37047 10.1074/jbc.M506520200
97. Dutta, R. and Inouye, M. (2000) GHKL, an emergent ATPase/kinase superfamily Trends Biochem. Sci. 25, 24-28 10.1016/S0968-0004(99)01503-0
98. Obermann, W. M., Sondermann, H., Russo, A. A., Pavletich, N. P., and Hartl, F. U. (1998) In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis J. Cell Biol. 143, 901-910 10.1083/jcb.143.4.901
99. Ban, C., Junop, M., and Yang, W. (1999) Transformation of MutL by ATP binding and hydrolysis: a switch in DNA mismatch repair Cell 97, 85-97 10.1016/S0092-8674(00)80717-5
100. Guarne, A., Junop, M. S., and Yang, W. (2001) Structure and function of the N-terminal 40 kDa fragment of human PMS2: a monomeric GHL ATPase EMBO J. 20, 5521-5531 10.1093/emboj/20.19.5521
101. Nikaido, H. (2003) Molecular basis of bacterial outer membrane permeability revisited Microbiol. Mol. Biol. Rev. 67, 593-656 10.1128/MMBR.67.4.593-656.2003
102. Silver, L. L. (2011) Challenges of antibacterial discovery Clin. Microbiol. Rev. 24, 71-109 10.1128/CMR.00030-10
103. Price, K. E., Chisholm, D. R., Godfrey, J. C., Misiek, M., and Gourevitch, A. (1970) Semisynthetic coumermycins: structure-activity relationships Appl. Microbiol. 19, 14-26
104. Reusser, F. and Dolak, L. A. (1986) Novenamine is the active moiety in novobiocin J. Antibiot. (Tokyo) 39, 272-274
105. Basarab, G. S., Hill, P. J., Garner, C. E., Hull, K., Green, O., Sherer, B. A., Dangel, P. B., Manchester, J. I., Bist, S., Hauck, S., Zhou, F., Uria-Nickelsen, M., Illingworth, R., Alm, R., Rooney, M., and Eakin, A. E. (2014) Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099) J. Med. Chem. 57, 6060-6082 10.1021/jm500462x
106. Manchester, J. I., Dussault, D. D., Rose, J. A., Boriack-Sjodin, P. A., Uria-Nickelsen, M., Ioannidis, G., Bist, S., Fleming, P., and Hull, K. G. (2012) Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV Bioorg. Med. Chem. Lett. 22, 5150-5156 10.1016/j.bmcl.2012.05.128
107. Tari, L. W., Li, X., Trzoss, M., Bensen, D. C., Chen, Z., Lam, T., Zhang, J., Lee, S. J., Hough, G., Phillipson, D., Akers-Rodriguez, S., Cunningham, M. L., Kwan, B. P., Nelson, K. J., Castellano, A., Locke, J. B., Brown-Driver, V., Murphy, T. M., Ong, V. S., Pillar, C. M., Shinabarger, D. L., Nix, J., Lightstone, F. C., Wong, S. E., Nguyen, T. B., Shaw, K. J., and Finn, J. (2013) Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents PLoS One 8, e84409 10.1371/journal.pone.0084409
108. Tari, L. W., Trzoss, M., Bensen, D. C., Li, X., Chen, Z., Lam, T., Zhang, J., Creighton, C. J., Cunningham, M. L., Kwan, B., Stidham, M., Shaw, K. J., Lightstone, F. C., Wong, S. E., Nguyen, T. B., Nix, J., and Finn, J. (2013) Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity Bioorg. Med. Chem. Lett. 23, 1529-1536 10.1016/j.bmcl.2012.11.032
109. Trzoss, M., Bensen, D. C., Li, X., Chen, Z., Lam, T., Zhang, J., Creighton, C. J., Cunningham, M. L., Kwan, B., Stidham, M., Nelson, K., Brown-Driver, V., Castellano, A., Shaw, K. J., Lightstone, F. C., Wong, S. E., Nguyen, T. B., Finn, J., and Tari, L. W. (2013) Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity Bioorg. Med. Chem. Lett. 23, 1537-1543 10.1016/j.bmcl.2012.11.073
110. Palmer, J. T. Benzothiazole Urea-Based Dual-Targeting DNA Supercoiling Inhibitors. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013, abstract F-410.
111. Eakin, A. E. and Sherer, B. A. Unpublished results.
112. Nikaido, H. and Thanassi, D. G. (1993) Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples Antimicrob. Agents Chemother. 37, 1393-1399 10.1128/AAC.37.7.1393
113. O'Shea, R. and Moser, H. E. (2008) Physicochemical properties of antibacterial compounds: implications for drug discovery J. Med. Chem. 51, 2871-2878 10.1021/jm700967e
114. Delcour, A. H. (2009) Outer membrane permeability and antibiotic resistance Biochim. Biophys. Acta 1794, 808-816 10.1016/j.bbapap.2008.11.005
115. Chen, S. (2012) Substrate specificity and kinetics of bacterial transmembrane transporters J. Membr. Sci. Technol. 2, 1000e105 10.4172/2155-9585.1000e105
116. Nagano, K. and Nikaido, H. (2009) Kinetic behavior of the major multidrug efflux pump AcrB of Escherichia coli Proc. Natl. Acad. Sci. U.S.A. 106, 5854-5858 10.1073/pnas.0901695106
117. Cai, H., Rose, K., Liang, L., Dunham, S., and Stover, C. (2009) Development of a liquid chromatography/mass spectrometry-based drug acumulation assay in Pseudomonas aeruginosa Anal. Biochem. 385, 321-325 10.1016/j.ab.2008.10.041
118. Davis, T. D., Gerry, C. J., and Tan, D. S. (2014) General platform for systematic quantitative evaluation of small-molecule permeability in bacteria ACS Chem. Biol. 9, 2535-2544 10.1021/cb5003015
119. Manchester, J. I., Buurman, E. T., Bisacchi, G. S., and McLaughlin, R. E. (2012) Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery J. Med. Chem. 55, 2532-2537 10.1021/jm201275d
120. http://www.imi.europa.eu/content/translocation.
121. Laurin, P., Ferroud, D., Schio, L., Klich, M., Dupuis-Hamelin, C., Mauvais, P., Lassaigne, P., Bonnefoy, A., and Musicki, B. (1999) Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B Bioorg. Med. Chem. Lett. 9, 2875-2880 10.1016/S0960-894X(99)00492-8
122. Laurin, P., Ferroud, D., Klich, M., Dupuis-Hamelin, C., Mauvais, P., Lassaigne, P., Bonnefoy, A., and Musicki, B. (1999) Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B Bioorg. Med. Chem. Lett. 9, 2079-2084 10.1016/S0960-894X(99)00329-7
123. Ferroud, D., Collard, J., Klich, M., Dupuis-Hamelin, C., Mauvais, P., Lassaigne, P., Bonnefoy, A., and Musicki, B. (1999) Synthesis and biological evaluation of coumarincarboxylic acids as inhibitors of gyrase B. L-rhamnose as an effective substitute for L-noviose Bioorg. Med. Chem. Lett. 9, 2881-2886 10.1016/S0960-894X(99)00493-X
124. Periers, A., Laurin, P., Ferroud, D., Haesslein, J., Klich, M., Dupuis-Hamelin, C., Mauvais, P., Lassaigne, P., Bonnefoy, A., and Musicki, B. (2000) Coumarin inhibitors of gyrase B with N-propargyloxy-carbamate as an effective pyrrole bioisostere Bioorg. Med. Chem. Lett. 10, 161-165 10.1016/S0960-894X(99)00654-X
125. Musicki, B., Periers, A. -., Laurin, P., Ferroud, D., Benedetti, Y., Lachaud, S., Chatreaux, F., Haesslein, J. -., Iltis, A., Pierre, C., Khider, J., Tessot, N., Airault, M., Demassey, J., Dupuis-Hamelin, C., Lassaigne, P., Bonnefoy, A., Vicat, P., and Klich, M. (2000) Improved antibacterial activities of coumarin antibiotics bearing 5′,5′-dialkylnoviose: biological activity of RU79115 Bioorg. Med. Chem. Lett. 10, 1695-1699 10.1016/S0960-894X(00)00304-8
126. Musicki, B., Periers, A., Piombo, L., Laurin, P., Klich, M., Dupuis-Hamelin, C., Lassaigne, P., and Bonnefoy, A. (2003) Noviose mimics of the coumarin inhibitors of gyrase B Tetrahedron Lett. 44, 9259-9262 10.1016/j.tetlet.2003.10.076
127. Musicki, B., Periers, A., Tessot, N., and Klich, M. (2004) Synthesis of the 4′-desmethoxy analogue of RU79115 J. Serb. Chem. Soc. 69, 855-859 10.2298/JSC0411855M
128. Schio, L., Chatreaux, F., Loyau, V., Murer, M., Ferreira, A., Mauvais, P., Bonnefoy, A., and Klich, M. (2001) Fine Tuning of physico-chemical parameters to optimize a new series of novobiocin analogues Bioorg. Med. Chem. Lett. 11, 1461-1464 10.1016/S0960-894X(01)00257-8
129. Lafitte, D., Lamour, V., Tsvetkov, P. O., Makarov, A. A., Klich, M., Deprez, P., Moras, D., Briand, C., and Gilli, R. (2002) DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5′-methyl group of the noviose Biochemistry 41, 7217-7223 10.1021/bi0159837
130. Mauvais, P., Dupuis-Hamelin, C., Lassaigne, P., Bonnefoy, A., Schoot, B., Musicki, B., Haesslein, J., Derroud, D., Klich, M., Rowlands, D., Lorenzon, G., Vicat, P., Julien, P., and Hamon, G. Novel coumarin antibiotics: II. in vitro and in vivo acticity of RU79115. Abstract F563. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 26-29, 1999.
131. Bell, W., Block, M. H., Cook, C., Grant, J. A., and Timms, D. (1997) Design, synthesis and evaluation of a novel series of spiroketals based on the structure of the antibacterial gyrase inhibitor novobiocin J. Chem. Soc., Perkin Trans. 1 2789-2801 10.1039/a700647k
132. Poyser, J. P., Telford, B., Timms, D., Block, M. H., and Hales, N. J. WO9901442A1, 1999.
133. Block, M. H. and Nichols, W. W. In Design of antibacterial agents; Sussman, M., Ed.; Molecular Medical Microbiology; Academic Press: 2001; Vol. 1, pp 609-626.
134. Ward, W. H. and Holdgate, G. A. (2001) Isothermal titration calorimetry in drug discovery Prog. Med. Chem. 38, 309-376
135. Lübbers, T., Angehrn, P., Gmünder, H., Herzig, S., and Kulhanek, J. (2000) Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors Bioorg. Med. Chem. Lett. 10, 821-826 10.1016/S0960-894X(00)00109-8
136. Boehm, H. J., Boehringer, M., Bur, D., Gmuender, H., Huber, W., Klaus, W., Kostrewa, D., Kuehne, H., Luebbers, T., Meunier-Keller, N., and Mueller, F. (2000) Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening J. Med. Chem. 43, 2664-2674 10.1021/jm000017s
137. Lübbers, T., Angehrn, P., Gmünder, H., and Herzig, S. (2007) Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors Bioorg. Med. Chem. Lett. 17, 4708-4714 10.1016/j.bmcl.2006.12.065
138. Tanitame, A., Oyamada, Y., Ofuji, K., Suzuki, K., Ito, H., Kawasaki, M., Wachi, M., and Yamagishi, J. (2004) Potent DNA gyrase inhibitors; novel 5-vinylpyrazole analogues with Gram-positive antibacterial activity Bioorg. Med. Chem. Lett. 14, 2863-2866 10.1016/j.bmcl.2004.03.045
139. Tanitame, A., Oyamada, Y., Ofuji, K., Kyoya, Y., Suzuki, K., Ito, H., Kawasaki, M., Nagai, K., Wachi, M., and Yamagishi, J. (2004) Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity Bioorg. Med. Chem. Lett. 14, 2857-2862 10.1016/j.bmcl.2004.03.044
140. Charifson, P., Stamos, D., Badia, M., Grillot, A., Ronkin, S., and Trudeau, M. WO2001052845, 2001.
141. Charifson, P., Bellon, S., Stamos, D., Badia, M., Grillot, A., Ronkin, S., Murcko, M., and Trudeau, M. WO2001052846, 2001.
142. Ronkin, S. M., Badia, M., Bellon, S., Grillot, A., Gross, C. H., Grossman, T. H., Mani, N., Parsons, J. D., Stamos, D., Trudeau, M., Wei, Y., and Charifson, P. S. (2010) Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase Bioorg. Med. Chem. Lett. 20, 2828-2831 10.1016/j.bmcl.2010.03.052
143. Yager, K. M., Almassy, B., Bensen, D., Chen, S., Chu, S., Cunningham, M., Feher, V., Khalili, M., Levin, J., Li, X., Margosiak, S., Nie, Z., Sprankle, K., Tedder, M., Vasu, S., and Appelt, K. Structure-Based Discovery and Optimization of Novel Antibacterials Directed against DNA Topoisomerases. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004, abstract F-1953.
144. Vasu, S., Barkho, W., Levin, J., Yager, K., and Appelt, K. Pharmacokinetics of QX-2987 and QX-3073 in Mouse, Rat and Dog 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004, abstract F-1958.
145. Levin, J. C., Barkho, W., Vasu, S., Yager, K., and Appelt, K. Anti-microbial activity of QX-2987 and QX-3073 in a murine gram-positive thigh infection model. Abstract F-1957. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004.
146. Grant, C. C. R., Atwell, C. L., Francis, K. A., Marques, N. R., Levin, J. Y. K., and Appelt, K. Time-Kill Kinetics, Post-Antibiotic Effect and Resistance Profile of Two Novel Anti-Microbials Targeting Both Bacterial DNA Gyrase and Topoisomerase IV. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, 2004, abstract F-1956.
147. Cunningham, M. L., Bensen, D., Chen, S. J., Margosiak, S., Yager, K., Levin, J., Gajiwala, K., and Appelt, K. Potent Inhibitors of DNA Topoisomerase IV: In Vitro Biochemical Properties. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, 2004; abstract F-1954
148. Atwell, C. L., Francis, K. A., Marques, N. R., Grant, C. C. R., Levin, J., Yager, K., and Appelt, K. Antimicrobial Activity of QX-2987 and QX-3073, Potent Inhibitors of Bacterial Gyrase B and Topoisomerase IV. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, 2004; abstract F-1955.
149. Yager, K., Chu, S., Appelt, K., and Li, X. US 20050054697A1, 2005.
150. Rose, K., Yang, Y. S., Sciotti, R., and Cai, H. (2009) Structure-activity relationship (SAR): effort towards blocking N-glucuronidation of indazoles (PF-03376056) by human UGT1A enzymes Drug Metab. Lett. 3, 28-34 10.2174/187231209787176371
151. Zhana, J.;, Cross, J., Yang, Q., Mesleh, M., Romero, J., Wang, B., Bevan, D., Hall, K., Epie, J., Moy, T., Daniel, A., Shotwell, J., Chamberlain, B., Carter, N., Ryan, D., Metcalf, C., Silverman, J., Nguyen, K., Lippa, B., and Dolle, R. The Discovery of Pyrazolopyridones As a Novel Class of Gyrase B Inhibitors through Fragment-and Structure-Based Drug Discovery: SAR Studies and Antibacterial Activity. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, CO, 2013; abstract F-1224.
152. Uria-Nickelsen, M., Neckermann, G., Sriram, S., Andrews, B., Manchester, J. I., Carcanague, D., Stokes, S., and Hull, K. G. (2013) Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines Int. J. Antimicrob. Agents 41, 363-371 10.1016/j.ijantimicag.2012.12.001
153. Boriack-Sjodin, A., Carcanague, D. R., Dussault, D. D., Hatoum-Mokdad, H., Hull, K. G., Ioannidis, G., Manchester, J. I., McGuire, H. M., McKinney, D. C., and Stokes, S. WO2010038081A2, 2010.
154. Hickey, E. (2007) Tools to define the relevance of PK/PD parameters to the efficacy, toxicity, and emergence of resistance of antimicrobials Curr. Opin. Drug Discovery Dev. 10, 49-52
155. Newman, J. and Eakin, A. E. Unpublished results.
156. Cunningham, M. L., Kwan, B. P., Nelson, K. J., Bensen, D. C., and Shaw, K. J. (2013) Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay J. Biomol. Screen. 18, 1018-1026 10.1177/1087057113487208
157. Eakin, A. E., Green, O., Hales, N., Walkup, G. K., Bist, S., Singh, A., Mullen, G., Bryant, J., Embrey, K., Gao, N., Breeze, A., Timms, D., Andrews, B., Uria-Nickelsen, M., Demeritt, J., Loch, J. T., 3rd, Hull, K., Blodgett, A., Illingworth, R. N., Prince, B., Boriack-Sjodin, P. A., Hauck, S., MacPherson, L. J., Ni, H., and Sherer, B. (2012) Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents Antimicrob. Agents Chemother. 56, 1240-1246 10.1128/AAC.05485-11
158. Sherer, B. A., Hull, K., Green, O., Basarab, G., Hauck, S., Hill, P., Loch, J. T., III, Mullen, G., Bist, S., Bryant, J., Boriack-Sjodin, A., Read, J., DeGrace, N., Uria-Nickelsen, M., Illingworth, R. N., and Eakin, A. E. (2011) Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy Bioorg. Med. Chem. Lett. 21, 7416-7420 10.1016/j.bmcl.2011.10.010
159. Uria-Nickelsen, M., Blodgett, A., Kamp, H., Eakin, A., Sherer, B., and Green, O. (2013) Novel DNA gyrase inhibitors: microbiological characterisation of pyrrolamides Int. J. Antimicrob. Agents 41, 28-35 10.1016/j.ijantimicag.2012.08.017
160. Eakin, A. E. and Mueller, J. Unpublished results.
161. Soneda, T., Takeshita, H., Kagoshima, Y., Yamamoto, Y., Hosokawa, T., Konosu, T., Masuda, N., Uchida, T., Achiwa, I., Kuroyanagi, J., Fujisawa, T., Yokomizo, A., and Noguchi, T. WO2009084614, 2009.
162. Bellon, S., Parsons, J. D., Wei, Y., Hayakawa, K., Swenson, L. L., Charifson, P. S., Lippke, J. A., Aldape, R., and Gross, C. H. (2004) Crystal structures of Escherichia coli topoisomerase IV ParE Subunit (24 and 43 Kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase Antimicrob. Agents Chemother. 48, 1856-1864 10.1128/AAC.48.5.1856-1864.2004
163. Charifson, P. S., Grillot, A. L., Grossman, T. H., Parsons, J. D., Badia, M., Bellon, S., Deininger, D. D., Drumm, J. E., Gross, C. H., LeTiran, A., Liao, Y., Mani, N., Nicolau, D. P., Perola, E., Ronkin, S., Shannon, D., Swenson, L. L., Tang, Q., Tessier, P. R., Tian, S. K., Trudeau, M., Wang, T., Wei, Y., Zhang, H., and Stamos, D. (2008) Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships J. Med. Chem. 51, 5243-5263 10.1021/jm800318d
164. Grillot, A., Charifson, P., Stamos, D., Liao, Y., Badia, M., and Trudeau, M. WO2002060879A2, 2002.
165. Finn, J. (2013) Evaluation of WO2012177707 and WO2012097269: Vertex's phosphate prodrugs of gyrase and topoisomerase antibacterial agents Expert Opin. Ther. Pat. 23, 1233-1237 10.1517/13543776.2013.820707
166. Perola, E., Stamos, D., Grillot, A., Ronkin, S., Wang, T., LeTiran, A., Tang, Q., Deininger, D. D., Liao, Y., Tian, S., Drumm, J. E., Nicolau, D. P., Tessier, P. R., Mani, N., Grossman, T. H., and Charifson, P. S. (2014) Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy Bioorg. Med. Chem. Lett. 24, 2177-2181 10.1016/j.bmcl.2014.03.022
167. Grillot, A. L., Le Tiran, A., Shannon, D., Krueger, E., Liao, Y., O'Dowd, H., Tang, Q., Ronkin, S., Wang, T., Waal, N., Li, P., Lauffer, D., Sizensky, E., Tanoury, G. J., Perola, E., Grossman, T. H., Doyle, T., Hanzelka, B., Jones, S., Dixit, V., Ewing, N., Liao, S., Boucher, B., Jacobs, M., Bennani, Y. L., and Charifson, P. S. (2014) Second-generation antibacterial benimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability J. Med. Chem. 57, 8792-8816 10.1021/jm500563g
168. Bennani, Y. L., Charifson, P. S., Grillot, A., Letiran, A., and O'Dowd, H. WO2012177707A1, 2012.
169. Le, T., Grillot, A., Charifson, P. S., Bennani, Y. L., O'Dowd, H., and Perola, E. WO2012097269A1, 2012.
170. Locher, C. P., Bennani, Y. L., Grillot, A., O'Dowd, H., Perola, E., and Le Tiran, A. WO2014014845 A1, 2014.
171. Hanzelka, B., Stokes, S. S., Fowlie, A. J., Jeverica, S., and Unemo, M. VXc-486, a Novel Dual Dargeting GyrB/ParE Inhibitor for the Treatment of Bacterial Infections: Potent Antimicrobial Activity against Antibiotic Sensitive and Resistant Isolates of Neisseria gonorrhoeae. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2014, abstract F-269.
172. Locher, C. P.;, Hanzelka, B. L., Shoen, C. M., Sklaney, M., DeStefano, L., and Cynamon, M. H. VXc-486, a Novel Dual Targeting GyrB/ParE Inhibitor for the Treatment of Bacterial Infections: Antibacterial Activity against Non-Tuberculosis Mycobacteria 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2014, abstract F-271.
173. Locher, C. P., Jones, S. M., Hanzelka, B. L., Shoen, C. M., Cynamon, M. H., Ngwane, A., Van Helden, P., Betoudji, F., Nuermberger, E. L., and Thomson, J. A. VXc-486, a Novel Dual Targeting GyrB/ParE Inhibitor for the Treatment of Bacterial Infections: VXc-486 Prodrug Sterilizes Mycobacterium tuberculosis Infection in Combination with Anti-Mycobacterial Drugs in vivo. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2014; abstract F-270.
174. O'Dowd, H., Shannon, D., Chandupatla, K., Bennani, Y., Engtrakul, J., Ye, Z., Yeola, S., Liao, S., Ewing, N., Jones, P., Tsao, H., Kolaczkowski, E., Donahue, S., Seliniotakis, R., Bao, N., Tsai, A., Shawgo, R., Dixit, V., Jones, S., McNeil, C., Song, B., Macikenas, D., Grillot, A., and Charifson, P. Vxc-486, a Novel Dual Targeting GyrB-ParE Inhibitor for the Treatment of Bacterial Infections: Discovery and Characterization of a Water-Soluble Prodrug. 54th Interscience Conference for Antimicrobial Agents and Chemotherapy, Washington DC, 2014, abstract F-273.
175. Tsai, A. W., Dixit, V., McNeil, C. F., Germann, U., Belioz-Seux, F., and Jones, S. M. VXc-486, a Novel Dual Targeting GyrB/ParE Inhibitor for the Treatment of Bacterial Infections: Pharmacokinetic/Pharmacodynamic Analysis in a Mouse Staphylococcus aureus Infection Model. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, 2014; abstract F-272
176. Shannon, D., Luisi, B., Krawiec, M., and Kuldip-Kimar, A. K. WO2012097273 A1, 2012.
177. Shannon, D., Luisi, B., Liao, Y., and Krawiec, M. WO2012097270 A1, 2012.
178. Shannon, D., Wang, T., and Giroux, S. WO2012097274 A1, 2012.
179. O'Dowd, H., Macikenas, D., and Song, B. Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phaosphate and salts thereof. 2014, WO2014015105 A1.
180. Sciotti, R. J., Starr, J. T., Richardson, C., Rewcastle, G. W., Palmer, B. D., Sutherland, H. S., Spicer, J. A., and Chen, H. WO2005089763A1, 2005.
181. Butler, D., Donnell, C., Chen, H., Hegde, V. R., Limberakis, C., Rasne, R. M., Sciotti, R. J., and Starr, J. T. WO2006038116A2, 2006.
182. Barbachyn, M. R. Personal communication.
183. Starr, J. T., Sciotti, R. J., Hanna, D. L., Huband, M. D., Mullins, L. M., Cai, H., Gage, J. W., Lockard, M., Rauckhorst, M. R., Owen, R. M., Lall, M. S., Tomilo, M., Chen, H., McCurdy, S. P., and Barbachyn, M. R. (2009) 5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV Bioorg. Med. Chem. Lett. 19, 5302-5306 10.1016/j.bmcl.2009.07.141
184. Haydon, D. R., Czaplewski, L. G., Palmer, N. J., Mitchell, D. R., Atherall, J. F., Steele, C. R., and Ladduwahetty, T. WO2007148093A1, 2007.
185. East, S. P., White, C. B., Barker, O., Barker, S., Bennett, J., Brown, D., Boyd, E. A., Brennan, C., Chowdhury, C., Collins, I., Convers-Reignier, E., Dymock, B. W., Fletcher, R., Haydon, D. J., Gardiner, M., Hatcher, S., Ingram, P., Lancett, P., Mortenson, P., Papadopoulos, K., Smee, C., Thomaides-Brears, H. B., Tye, H., Workman, J., and Czaplewski, L. G. (2009) DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity Bioorg. Med. Chem. Lett. 19, 894-899 10.1016/j.bmcl.2008.11.102
186. East, S. P., Czaplewski, L. G., and Haydon, D. J. In Designing Multi-Target Drugs; The Royal Society of Chemistry: 2012; pp 335-352; chapter 20.
187. 10th Annual Superbugs and Superdrugs Conference; London U.K., April 9th, 2008.
188. Axford, L. C., Agarwal, P. K., Anderson, K. H., Andrau, L. N., Atherall, J., Barker, S., Bennett, J. M., Blair, M., Collins, I., Czaplewski, L. G., Davies, D. T., Gannon, C. T., Kumar, D., Lancett, P., Logan, A., Lunniss, C. J., Mitchell, D. R., Offermann, D. A., Palmer, J. T., Palmer, N., Pitt, G. R., Pommier, S., Price, D., Narasinga Rao, B., Saxena, R., Shukla, T., Singh, A. K., Singh, M., Srivastava, A., Steele, C., Stokes, N. R., Thomaides-Brears, H. B., Tyndall, E. M., Watson, D., and Haydon, D. J. (2013) Design, synthesis and biological evaluation of alpha-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors Bioorg. Med. Chem. Lett. 23, 6598-6603 10.1016/j.bmcl.2013.10.058
189. Palmer, J. T., Barker, S., Bennett, J. M., Berry, J., Blair, M., Czaplewski, L. G., Collins, I., Davies, D., Haydon, D. J., Lancett, P., Logan, A., Lunniss, C., Morton, C., Pitt, G., Offermann, D., Offermann, L., Pommier, S., Price, D., Stokes, N., Thomaides-Brears, H., and Tucker, S. P. In Vitro and in Vivo Biology of Benzothiazole Urea-Based Dual Targeting DNA Supercoining Inhibitors for the Treatment of Bacterial Infections. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2012.
190. Bist, S., Eakin, A., Sherer, B., and Zhao, S. WO2011024004 A1, 2011.
191. Bist, S., Basarab, G., Manchester, J., and Sherer, B. In Discovery and Structure-Activity Relationship (SAR) of Novel Pyridylureas As Potent Antibacterial Agents; 247th American Chemical Society National Meeting, Dallas, TX; abstract MEDI 107; 2014.
192. Basarab, G. S., Manchester, J. I., Bist, S., Boriack-Sjodin, P. A., Dangel, B., Illingworth, R., Sherer, B. A., Sriram, S., Uria-Nickelsen, M., and Eakin, A. E. (2013) Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents J. Med. Chem. 56, 8712 10.1021/jm401208b
193. Bifulco, N., Choy, A. L., Quiroga, O., and Sherer, B. WO2010136817A1, 2010.
194. Gude, M., Hubschwerlen, C., and Panchaud, P. WO2012131588 A1, 2012.
195. Bur, D., Gude, M., Hubschwerlen, C., and Panchaud, P. WO2011121555 A1, 2011.
196. Tyndall, E. M., Czaplewski, L. G., Fishwick, C.; Gordon, W., Yule, I. A., Mitchell, J. P., Anderson, K. H., Pitt, G., and Robert, W. WO2013091011A1, 2013.
197. Yule, I. A., Czaplewski, L. G., Pommier, S., Davies, D. T., Narramore, S. K., and Fishwick, C. W. (2014) Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: Structure based design, synthesis, SAR and antimicrobial activity Eur. J. Med. Chem. 86C, 31-38 10.1016/j.ejmech.2014.08.025
198. Davis, H. E., McGuire, H. M., Stokes, S. S., Durand-Reville, T., and Ioannidis, G. Design, Synthesis and Antibacterial Activity of Azaindole Inhibitors of ParE/GyrB with Improved Properties for the Treatment of Gram-Positive Bacterial Infections; 248th American Chemical Society National Meeting, San Francisco, CA; abstract MEDI 86; 2014.
199. Zhang, J., Cross, J., Yang, Q., Mesleh, M., Romero, J., Wang, B., Bevan, D., Hall, K., Epie, F., Moy, T., Daniel, A., Shotwell, J., Chamberlain, B., Carter, N., Ryan, D., Metcalf, C., Silverman, J., Nguyen, K., Lippa, B., and Dolle, R. The Discovery of Pyrazolopyridones as a Novel Class of Gyrase B inhibitors through fragment- and structure-based drug discovery: SAR studies and Antibacterial Activity 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013; abstract F-1224.
200. Musicki, B. Personal communication.
201. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., and Pangalos, M. N. (2014) Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework Nat. Rev. Drug Discovery 13, 419-431 10.1038/nrd4309
202. Ishikawa, T., Matsunaga, N., Tawada, H., Kuroda, N., Nakayama, Y., Ishibashi, Y., Tomimoto, M., Ikeda, Y., Tagawa, Y., Iizawa, Y., Okonogi, K., Hashiguchi, S., and Miyake, A. (2003) TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties Bioorg. Med. Chem. 11, 2427-2437 10.1016/S0968-0896(03)00126-3
203. Im, W. B., Choi, S. H., Park, J. Y., Choi, S. H., Finn, J., and Yoon, S. H. (2011) Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent Eur. J. Med. Chem. 46, 1027-1039 10.1016/j.ejmech.2011.01.014
204. Zeitlinger, M. A., Derendorf, H., Mouton, J. W., Cars, O., Craig, W. A., Andes, D., and Theuretzbacher, U. (2011) Protein binding: do we ever learn? Antimicrob. Agents Chemother. 3067-3074 10.1128/AAC.01433-10
205. Gonzalez, D., Schmidt, S., and Derendorf, H. (2013) Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents Clin. Micro. Rev. 26, 274-288 10.1128/CMR.00092-12
206. Payne, D. J., Gwynn, M. N., Holmes, D. J., and Pompliano, D. L. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discovery 6, 29-40 10.1038/nrd2201
207. Lu, J., Patel, S., Sharma, N., Soisson, S. M., Kishii, R., Takei, M., Fukuda, Y., Lumb, K. J., and Singh, S. B. (2014) Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode ACS Chem. Biol. 10.1016/j.chembiol.2014.10.015
208. Sawa, R., Takahashi, Y., Hashizume, H., Sasaki, K., Ishizaki, Y., Umekita, M., Hatano, M., Abe, H., Watanabe, T., Kinoshita, N., Homma, Y., Hayashi, C., Inoue, K., Ohba, S., Masuda, T., Arakawa, M., Kobayashi, Y., Hamada, M., Igarashi, M., Adachi, H., Nishimura, Y., and Akamatsu, Y. (2012) Amycolamicin: a novel broad-spectrum antibiotic inhibiting bacterial topoisomerase Chemistry 18, 15772-15781 10.1002/chem.201202645
209. Projan, S. J. (2003) Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427-430 10.1016/j.mib.2003.08.003
210. Sertkaya, A., Eyraud, J., Birkenbach, A., Franz, C., Ackerley, N., Overton, V., and Outterson, K. Analytical framework for examining the value of antibacterial products. U.S. Department of Health and Human Services report, 2014, HHSP23337004T.
211. Scriabine, A. In Discovery and Development of Major Drugs Currently in Use; Landau, R., Achilladelis, B., and Scriabine, A., Eds.; Pharmaceutical Innovation; Chemical Heritage Foundation: Philadelphia, 1999; pp 148.
212. Helfand, W. H., Woodruff, H. B., Coleman, K. M., and Cowen, D. L. In Wartime Industrial Development of Penicillin in the United States; Parascandola, J., Ed.; The History of Antibiotics: A Symposium; American Institute of the History of Pharmacy: Madison, WI, 1980; pp 31-56.
213. Kahn, E. J. All in a Century. The First 100 Years of Eli Lilly and Company; Lilly internal publication: 1975; pp 133.
214. Greenwood, D. Antimicrobial Drugs. Chronicle of a Twentieth Century Medical Triumph; Oxford University Press: Oxford, U.K., 2008; pp 209-268.
215. Anderson, R. C., Griffity, R. S., Higgins, H. M., and Pettinga, C. D. (1961) Symposium: How a Drug is Born Cincinnati J. Med. 42, 49
216. Vagelos, R. and Galambos, L. Medicine, Science, and Merck; Cambridge University Press: Cambridge, U.K., 2004; pp 164.
217. Finland, M., Kirby, W. M., Chabbert, Y. A., Chain, E. B., Dowling, H. F., Garrod, L. P., Pettinga, C. W., and Todd, A. C. (1965) Round table: are new antibiotics needed? Antimicrob. Agents Chemother. (Bethesda) 5, 1107-1114
218. Berdy, J. (1974) Recent developments of antibiotic research and classification of antibiotics according to chemical structure Adv. Appl. Microbiol. 18, 309-406
219. Chan, P. F., Holmes, D. J., and Payne, D. J. (2005) Finding the gems using genomic discovery: antibacterial drug discovery strategies-the successes and the challenges Drug Discovery Today 519 10.1016/j.ddstr.2004.11.003
220. Butler, M. S., Blaskovich, M. A., and Cooper, M. A. (2013) Antibiotics in the clinical pipeline in 2013 J. Antibiot. (Tokyo) 66, 571-591 10.1038/ja.2013.86
221. Barrett, J. F. (2005) Can biotech deliver new antibiotics? Curr. Opin. Microbiol. 8, 498-503 10.1016/j.mib.2005.08.007
222. Mossialos, E., Morel, C., Edwards, S., Berenson, J., Gemmill-Toyama, M., and Brogan, D. Policies and Incentives for Promoting Innovation in Antibiotic Research; London School of Economics and Political Science, 2009; p 199.
223. Garber, K. (2014) The cancer drug that almost wasn't Science 345, 865-867 10.1126/science.345.6199.865
224. Tomayko, J. F., Rex, J. H., Tenero, D. M., Goldberger, M., and Eisenstein, B. I. (2014) The challenge of antimicrobial resistance: new regulatory tools to support product development Clin. Pharmacol. Ther. 10.1038/clpt.2014.107
225. Young, D. US Capitol Capsule: What's Life & Limb Worth? Gauging Antibiotic's Value. Scrip July 21, 2014.
226. Spellberg, B. and Rex, J. H. (2013) The value of single-pathogen antibacterial agents Nat. Rev. Drug Discovery 12, 963-c1 Epub 2013 Nov 15. 10.1038/nrd3957-c1
227. Karlin, S. Antibiotic Trial Network Could Emerge from FDA/NIH Workshop. Pink Sheet Daily July 7, 2014, 29140707001.
228. Spellberg, B. (2014) The future of antibiotics Crit. Care 18, 228 10.1186/cc13948
229. Laponogov, I., Veselkov, D. A., Crevel, I. M., Pan, X., Fisher, L. M., and Sanderson, M. R. (2013) Structure of an 'open' clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport Nucleic Acids Res. 41, 9911-9923 10.1093/nar/gkt749
230. Brino, L., Urzhumtsev, A., Mousli, M., Bronner, C., Mitschler, A., Oudet, P., and Moras, D. (2000) Dimerization of Escherichia coli DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center J. Biol. Chem. 275, 9468-9475 10.1074/jbc.275.13.9468
231. Schmidt, B. H., Osheroff, N., and Berger, J. M. (2012) Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity Nat. Struct. Mol. Biol. 19, 1147-1154 10.1038/nsmb.2388
232. Coulson, C. J. and Smith, V. J. (1981) Coumarin antibiotic binding to human albumin Biochem. Pharmacol. 30, 447-452 10.1016/0006-2952(81)90629-8
233. Alt, S., Mitchenall, L. A., Maxwell, A., and Heide, L. (2011) Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics J. Antimicrob. Chemother. 66, 2061-2069 10.1093/jac/dkr247
234. Benet, L. Z., Broccatelli, F., and Oprea, T. I. (2011) BDDCS applied to over 900 drugs AAPS J. 13, 519-547 10.1208/s12248-011-9290-9